Becton, Dickinson and Company (BDX) Shares Sold by EagleClaw Capital Managment LLC

EagleClaw Capital Managment LLC lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 9.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,776 shares of the medical instruments supplier’s stock after selling 500 shares during the quarter. EagleClaw Capital Managment LLC’s holdings in Becton, Dickinson and were worth $937,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in Becton, Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 240 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in Becton, Dickinson and by 8.1% during the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after acquiring an additional 51 shares in the last quarter. Harfst & Associates Inc. increased its holdings in Becton, Dickinson and by 46.4% during the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 221 shares in the last quarter. Harvest Fund Management Co. Ltd increased its holdings in Becton, Dickinson and by 82.8% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock valued at $146,000 after acquiring an additional 338 shares in the last quarter. Finally, Acrospire Investment Management LLC increased its holdings in Becton, Dickinson and by 259.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock valued at $162,000 after acquiring an additional 600 shares in the last quarter. Institutional investors and hedge funds own 88.60% of the company’s stock.

BDX has been the subject of several recent research reports. Royal Bank of Canada restated a “hold” rating and set a $210.00 target price on shares of Becton, Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research downgraded shares of Becton, Dickinson and from a “hold” rating to a “sell” rating in a report on Monday, October 9th. Stifel Nicolaus restated a “buy” rating and set a $245.00 target price on shares of Becton, Dickinson and in a report on Friday, November 3rd. Morgan Stanley raised their target price on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Wells Fargo & Company restated a “positive” rating and set a $235.00 target price (up from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Becton, Dickinson and presently has a consensus rating of “Buy” and an average target price of $217.08.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at $218.94 on Thursday. Becton, Dickinson and Company has a 12 month low of $161.50 and a 12 month high of $229.68. The stock has a market cap of $49,924.97, a PE ratio of 23.08, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The company had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. During the same period last year, the company earned $2.12 EPS. The firm’s revenue for the quarter was down 2.0% compared to the same quarter last year. sell-side analysts predict that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be paid a dividend of $0.75 per share. This is a boost from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 annualized dividend and a dividend yield of 1.37%. The ex-dividend date of this dividend is Thursday, December 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 64.52%.

ILLEGAL ACTIVITY NOTICE: This report was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://stocknewstimes.com/2017/12/14/becton-dickinson-and-company-bdx-shares-sold-by-eagleclaw-capital-managment-llc.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply